March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pathological Retinal Neovascularization In Oxygen-induced Retinopathy Is Increased In Timp3-/- Mice, And Inhibited By Intravitreal Injection Of Erlotinib
Author Affiliations & Notes
  • Nina J. Jonsson
    Department of Ophthalmology, Weill Cornell Medical College, New York, New York
    Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York
  • Gisela Weskamp
    Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York
  • Krzysztof Glomski
    Biochemistry, Cell and Molecular Biology Program, Weill Medical College of Cornell University, New York, New York
  • Steven L. Swendeman
    Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York
  • Rama Khokha
    Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada
  • Carl P. Blobel
    Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York
    Biochemistry, Cell and Molecular Biology Program, Weill Medical College of Cornell University, New York, New York
  • Footnotes
    Commercial Relationships  Nina J. Jonsson, None; Gisela Weskamp, None; Krzysztof Glomski, None; Steven L. Swendeman, None; Rama Khokha, None; Carl P. Blobel, None
  • Footnotes
    Support  Research grant, Dr. Werner Jackstaedt Foundation, Wuppertal Germany (NJJ); GM64750 (CPB, GW, SLS); NHLBI, T32 GM007739-31S1 (KG)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2548. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nina J. Jonsson, Gisela Weskamp, Krzysztof Glomski, Steven L. Swendeman, Rama Khokha, Carl P. Blobel; Pathological Retinal Neovascularization In Oxygen-induced Retinopathy Is Increased In Timp3-/- Mice, And Inhibited By Intravitreal Injection Of Erlotinib. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2548.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Pathological neovascularization is causal for the development of proliferative retinopathies. Previous studies have shown that pathological neovascularization is reduced by inactivation of ADAM17, which is important for EGFR signaling by cleaving and activating several EGFR-ligands. The tissue inhibitor of metalloproteinases-3 (TIMP-3) is a natural inhibitor of ADAM17. In this study we investigated whether intravitreal injection of the EGFR-inhibitor Erlotinib (Tarceva®), an EGFR antagonist, inhibits pathological neovascularization after oxygen-induced retinopathy (OIR). Moreover, we tested how the lack of TIMP3 affected retinal neovascularization in mice following OIR.

Methods: : Wild-type mice and Timp-3-/- mice underwent OIR (75% oxygen for 5 days starting at postnatal day 7 (P7), followed by 21% oxygen for additional 5 days). On P12 wild-type mice underwent a single intravitreal injection (0.5µl) of Erlotinib (20µM) or carrier control. The central avascular area and the development of neovascular tufts were measured at P17.

Results: : Mice injected with Erlotinib developed fewer neovascular tufts above the internal limiting membrane when compared to the untreated eye of a littermate, but vessel re-growth into the avascular area was not affected. Timp-3-/- mice showed greater revascularization and development of more neovascular tufts above the internal limiting membrane.

Conclusions: : These studies demonstrate that Erlotinib is able to inhibit pathological neovascularization in mouse retina, most likely due to inactivation of the EGFR. These studies also suggest that TIMP-3 is a natural negative regulator of pathological neovascularization. Erlotinib, and potentially also TIMP3, could be used as anti-angiogenic compounds to prevent proliferative retinopathies.

Keywords: retinal neovascularization • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×